Literature DB >> 2510928

Modulation of ovarian carcinoma tumor marker CA-125 by gamma-interferon.

C Marth1, L C Fuith, G Böck, G Daxenbichler, O Dapunt.   

Abstract

Interferons are known to modulate several cellular functions by the induction of different proteins. In our study a gamma-interferon-mediated presentation of one of the most important ovarian tumor markers (CA-125) on the cell surface was demonstrated using two ovarian carcinoma cell lines in vitro (HTB-77 and SKOV-3). This induction was found to be dependent on an intact protein biosynthesis. The gamma-interferon effect reached a maximum on the third day of treatment. Under such conditions the CA-125 concentration was increased intracellularly, on the cell surface, and in the supernatant culture medium. The surface antigen was shed rapidly with a half-life of 1 day. The addition of dexamethasone to gamma-interferon treated HTB-77 cells improved CA-125 expression synergistically. HLA-DR and CA-125 expression was found to be regulated by interferons in different ways. The demonstration of CA-125 expression provides an important insight into the potential regulatory mechanism governing this tumor marker. Since interferons are naturally occurring substances as well as therapeutically administered agents, it seems necessary to pay attention to possible tumor marker modulation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510928

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity.

Authors:  M Chiron; J P Jaffrezou; P Carayon; C Bordier; F Roubinet; C Xavier; M Brandely; G Laurent
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Effects of interferon gamma on the proliferation and modulation of cell-surface structures of human ovarian carcinoma cell lines.

Authors:  V J Möbus; W Asphal; P G Knapstein; R Kreienberg
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Changes in CA125 release and surface expression caused by drugs in uterine cervix adenocarcinoma cells.

Authors:  T Nakai; H Sakahara; K Endo; M Shirato; H Kobayashi; M Hosono; T Saga; M Sakamoto; J Konishi
Journal:  Ann Nucl Med       Date:  1993-08       Impact factor: 2.668

4.  Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.

Authors:  Lana Bruney; Kaitlynn C Conley; Natalie M Moss; Yueying Liu; M Sharon Stack
Journal:  Biol Chem       Date:  2014-10       Impact factor: 3.915

5.  Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.

Authors:  G H Windbichler; H Hausmaninger; W Stummvoll; A H Graf; C Kainz; J Lahodny; U Denison; E Müller-Holzner; C Marth
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

6.  Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease.

Authors:  C Natoli; C Garufi; N Tinari; M D'Egidio; G Lesti; L A Gaspari; R Visini; S Iacobelli
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.